Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Strategic Collaboration with ARUP

17 July 2009

[image reference is broken]

In July 2009 UCL announced a strategic collaboration and training partnership with ARUP which follows closely on the important strategic partnership announced this year with GlaxoSmithKline.

Alain Marcetteau, CEO of ARUP, has been a valued member of the UCL Research Challenges Board, set up in 2006. The UCL-ARUP Memorandum of Understanding is stimulating a number of  initiatives.

Related items: